

IN THE CLAIMS:

Please delete claims 1-18, without prejudice, and insert the following new claims:

--- 19. A method for prevention of graft rejection in a lung transplant recipient comprising administering to the recipient directly following transplantation an aerosolized composition consisting essentially of :

- (i) a dose of cyclosporine in an amount effective to prevent graft rejection;
- (ii) and a propellant.

20. A method for prevention of graft rejection in a lung transplant recipient comprising administering to the recipient directly following transplantation an aerosolized composition consisting essentially of:

- (i) a dose of cyclosporine in an amount effective to prevent graft rejection;
- (ii) a dry powder; and
- (iii) a propellant.

21. (New) A method for prevention of graft rejection in a lung transplant recipient comprising administering to the recipient directly following transplantation an

PATENT

aerosolized composition consisting essentially of :

Sub
31
cont

- (i) a dose of cyclosporine in an amount effective to prevent graft rejection;
- (ii) an organic solvent; and
- (iii) a propellant.

22. (New) The method of claim 19, 20 or 21 wherein the dose of cyclosporine is sufficient to achieve deposition levels ranging between 15 and 30 mg in a lung.

23. (New) The method of claim 19, 20 or 21 wherein the aerosolized composition is co-administered with a second immunosuppressive agent.

24. (New) The method of claim 19, 20 or 21 wherein the aerosolized composition is co-administered with a anti-inflammatory reagent.

25. (New) A method for ameliorating pulmonary inflammation in a subject comprising administering to the subject an aerosolized composition consisting essentially of :

Sub
32

- (i) a dose of cyclosporine in an amount effective to inhibit or ameliorate pulmonary inflammation; and
- (ii) a propellant.

PATENT

26. (New) A method for ameliorating pulmonary inflammation in a subject comprising administering to the subject an aerosolized composition consisting essentially of :

- (i) a dose of cyclosporine in an amount effective to inhibit or ameliorate pulmonary inflammation;
- (ii) a dry powder; and
- (iii) a propellant.

27. (New) A method for ameliorating pulmonary inflammation in a subject comprising administering to the subject an aerosolized composition consisting essentially of :

- (i) a dose of cyclosporine effective to inhibit or ameliorate pulmonary inflammation;
- (ii) an organic solvent; and
- (iii) a propellant.

28. (New) The method of claim 25, 26 or 27 wherein the pulmonary inflammation is associated with asthma, sarcoidosis, emphysema, cystic fibrosis, idiopathic pulmonary fibrosis, chronic bronchitis, or allergic rhinitis.

29. (New) The method of claim 25, 26 or 27 wherein the dose of cyclosporine is sufficient to achieve deposition levels ranging between 5 and 30 mg in a lung.

PATENT

30. (New) A method for prevention of graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient an aerosolized composition consisting essentially of:

- (i) a dose of cyclosporine in an amount effective to prevent graft rejection;
- (ii) and a propellant.

31. (New) A method for prevention of graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient an aerosolized composition consisting essentially of:

- (i) a dose of cyclosporine in an amount effective to prevent graft rejection;
- (ii) a dry powder; and
- (iii) and a propellant.

32. (New) A method for prevention of graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient an aerosolized composition consisting essentially of:

- (i) a dose of cyclosporine in an amount effective to prevent graft rejection;

(ii) an organic solvent; and

(ii) and a propellant.

Sub
33
Cont

Rule
12b

33

34. (New) The method of claim 30, 31 or 32 wherein the dose of cyclosporine is sufficient to achieve circulating blood levels ranging between 50-250 ng/ml.

34

35. (New) The method of claim 30, 31 or 32 wherein the aerosolized composition is co-administered with a second immunosuppressive agent.

Rule
12b

35

36. (New) A method for inhibiting the immune response associated with a T-cell mediated immune disorder in a subject comprising administering to the non-lung transplant recipient an aerosolized composition consisting essentially of:

(i) a dose of cyclosporine in an amount effective to inhibit the

immune response associated with a T-cell mediated immune disorder;

and

(ii) a propellant.

Sub
34
Cont

36

37. (New) A method for inhibiting the immune response associated with a T-cell mediated immune disorder in a subject comprising administering to the non-lung transplant recipient an aerosolized composition consisting essentially of:

PATENT

- (i) a dose of cyclosporine in an amount effective to inhibit the immune response associated with a T-cell mediated immune disorder;
- (ii) a dry powder; and
- (iii) a propellant.

sub
B4
cont

37

38. (New) A method for inhibiting the immune response associated with a T-cell mediated immune disorder in a subject comprising administering to the non-lung transplant recipient an aerosolized composition consisting essentially of:

- (i) a dose of cyclosporine in an amount effective to inhibit the immune response associated with a T-cell mediated immune disorder;
- (ii) an organic solvent; and
- (iii) a propellant.

All
cont

Rule
126

38

39. (New) An aerosolized composition consisting essentially of:


- (i) cyclosporine in a dose effective to reduce pulmonary inflammation in subjects having pulmonary disorders; and
- (ii) a propellant.

39

40. (New) An aerosolized composition consisting essentially of:

- (i) cyclosporine in a dose effective to reduce pulmonary inflammation in

PATENT

Sub 34 cont  subjects having pulmonary disorders;
(ii) a dry powder; and
(iii) a propellant.


40
41. (New) An aerosolized composition consisting essentially of :

- (i) cyclosporine in doses effective to reduce pulmonary inflammation in subjects having pulmonary disorders;
- (ii) an organic solvent; and
- (ii) a propellant.

All Cont Rule 126 *41*
42. (New) The composition of claim 39, 40 or 41 wherein the aerosolized composition has a particle size of between 1 and 5 microns.

42
43. (New) The composition of Claim 39, 40 or 41 wherein the dose is sufficient to achieve concentration levels of between 5-15 mg of cyclosporine in a lung.

43
44. (New) The composition of Claim 41 wherein the organic solvent is propylene glycol.

Sub 35  *44*
45. (New) An aerosolized composition consisting essentially of :

PATENT

- (i) cyclosporine in doses effective to prevent development of an immune response that would lead to graft rejection in a transplant recipient;
and
(ii) a propellant.

45
46. (New) An aerosolized composition consisting essentially of :

- (i) cyclosporine in a dose sufficient to prevent development of an immune response that would lead to graft rejection in a transplant recipient;
(ii) a dry powder; and
(iii) a propellant.

46
47. (New) An aerosolized composition consisting essentially of :

- (i) cyclosporine in a dose sufficient to prevent development of an immune response that would lead to graft rejection in a transplant recipient;
(ii) an organic solvent; and
(ii) a propellant.

47
48. (New) The composition of claim 17 wherein the cyclosporine has a particle